Celladon revives IPO plans

NASDAQ IPO plans for Celladon Corp. (San Diego, Calif.) now seem to be on track. The gene therapy company postponed its IPO in November, citing market conditions. On Wednesday, Celladon filed an S-1A that no longer contains a share price or proposed number of shares. The company also dropped JPMorgan as an underwriter. Barclays; Stifel; and Wedbush PacGrow are still listed as underwriters.

Before postponing its IPO, Celladon had said it planned to sell 5 million shares at $14-$16. At the $15 midpoint, the company would have raised $75 million and been valued at $256.6 million (see BioCentury, Nov. 18, 2013). ...